A real-world study of evaluating real-world eculizumab use disease triggers, dialysis and plasma exchange/infusion (PE/PI) in patients with atypical hemolytic uremic syndrome (aHUS) using US claims data
Latest Information Update: 03 Jun 2021
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 03 Jun 2021 New trial record
- 20 May 2021 Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research